Compugen (NASDAQ:CGEN) Issues Earnings Results

Compugen (NASDAQ:CGEN) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02, FiscalAI reports. The business had revenue of $3.82 million during the quarter, compared to the consensus estimate of $1.28 million. Compugen had a return on equity of 38.04% and a net margin of 47.90%. During the same quarter in the prior year, the company earned ($0.07) earnings per share.

Here are the key takeaways from Compugen’s conference call:

• COM701’s MAIA-ovarian trial is fully enrolled, with results expected by the end of Q1 2027. The 62-patient study will be assessed on the magnitude and durability of separation from placebo; management estimated the placebo arm’s median progression-free survival at about four months, while noting that comparator studies were not directly comparable.
• Rilvegostomig has a major clinical catalyst expected in H2 2027, when AstraZeneca anticipates high-level results from the phase III ARTEMIDE-Biliary01 trial. Compugen also cited phase II lung-cancer survival and tolerability data as supportive, though the phase III outcome remains uncertain.
• Gilead’s phase I program for GS-0321 continues in monotherapy and combination settings, but Compugen did not disclose the study’s current stage, evidence of biological activity, or a timeline for clinical data. The company is eligible for up to $758 million in additional milestones plus tiered royalties, contingent on program progress.
• Compugen ended September with $117.5 million in cash and investments and said its cash runway should extend into 2029, assuming no further inflows. Q3 net loss narrowed to $5.8 million from $7.0 million a year earlier, while R&D spending was unchanged at $5.8 million.
• Compugen introduced UnigenX, an expansion of its discovery platform aimed at finding tumor-associated antigens for targeted immune therapies such as T-cell engagers. The company sees potential to create pipeline and partnership opportunities, but did not give a timeline for new clinical candidates.

Compugen Stock Up 0.2%

Shares of NASDAQ CGEN traded up $0.01 during trading on Wednesday, reaching $2.10. The company had a trading volume of 38,811 shares, compared to its average volume of 355,279. Compugen has a 12-month low of $1.43 and a 12-month high of $3.23. The stock has a market cap of $198.08 million, a PE ratio of 5.40 and a beta of 2.85. The business’s 50-day moving average is $2.23 and its 200 day moving average is $2.29.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CGEN. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Compugen in a research report on Monday, October 12th. Weiss Ratings reissued a “hold (c-)” rating on shares of Compugen in a research report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Compugen presently has a consensus rating of “Buy” and a consensus target price of $5.00.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines. Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.